- CFO Spotlights
- Profiles
- Thomas A. Fitzgerald, M.B.A.
Profile
Thomas A. Fitzgerald, M.B.A.
Chief Financial Officer, TransCode Therapeutics, Inc.
Former. First published here October 28, 2026; built from records as of October 28, 2026.
TransCode Therapeutics, Inc. named John Tattory to succeed Thomas A. Fitzgerald, M.B.A. on an interim basis, effective September 9, 2026.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) Pharmaceutical Preparations | Not stated | Former |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- September 9, 2026effective
TransCode Therapeutics, Inc. named John Tattory to succeed Thomas A. Fitzgerald, M.B.A. on an interim basis, effective September 9, 2026. Profile of John Tattory.
[1] Filing by TransCode Therapeutics, Inc., filed with the SEC on September 11, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, TransCode Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 11, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Thomas A. Fitzgerald, M.B.A. wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.